Date: 2013-05-03
Type of information: Halting of the trial
phase: 2-3
Announcement: discontinuation of the trial
Company: Bayer (Germany)
Product: BAY 86-6150 (recombinant factor VIIa (rFVIIa) protein)
Action mechanism:
Disease: patients with hemophilia A or B with inhibitors
Therapeutic area: Hematologic diseases - Genetic diseases - Rare diseases
Country:
Trial
details: The TRUST (TReatment with Unique recombinant rFVIIa STudy) trial is a Phase II/III, multicenter, open-label clinical study designed to assess the safety and efficacy of BAY 86-6150, a recombinant factor VIIa (rFVIIa) protein, in patients with hemophilia A or B with inhibitors.
Latest
news: * On May 3, 2013, Bayer HealthCare has announced that a Phase II/III trial evaluating the efficacy and safety of BAY 86-6150 in people with hemophilia A and hemophilia B with inhibitors has been discontinued. The hope that BAY 86-6150 might help patients with inhibitors to achieve better control of their disease could not be fulfilled due to the detection of a neutralizing antibody in the trial.
